Hikma Pharmaceuticals has signed an exclusive licensing and distribution agreement with Finland’s Orion for its new Easyhaler combination product for the treatment of asthma and chronic obstructive pulmonary disease. Under the terms of the agreement, Hikma has the exclusive rights to register, distribute, market and sell the product in all of its MENA markets, leveraging the company’s local presence, sales and marketing capabilities and regulatory expertise.
Category: Chronic Obstructive Pulmonary Disease
Phanerochaete sordida as a cause of pulmonary nodule in an immunocompromised patient: a case report
Phanerochaete sordida is a species of wood rotting fungus, which can degrade lignin, cellulose and hemicellulose contained in wood and other hard-to-biodegrade organic substances. However, to date, there have been no other reports demonstrating that P. sordida can infect humans.
Erdosteine Market – Current status and future trends
… deaths occur in developing and underdeveloped countries. Rising research and development activities, increasing health care insurance coverage, and growing adoption for treatment options are the other factors driving the global erdosteine market. On …
Hospital Readmissions for COPD
Chronic obstructive pulmonary disease exerts a major strain on the American healthcare system, mostly due to the high number of hospitalizations and emergency department visits associated with exacerbations.1 Generally, COPD is a treatable and manageable disease process for many patients in the early stages. However, the disease presents many morbidity and mortality issues that complicate management and care.
Health Ministry to launch population based prevention, screening and…
… the early stages. Screening for these conditions, which can be undertaken at the level of the sub centre or Primary health Centres helps early detection and also serves to raise health awareness among people to lead healthy lifestyles. Given that …
Global Pulmonary Drug Delivery Systems Market: Developing Economies…
… market such as AstraZeneca plc, CareFusion Corporation, GlaxoSmithKline plc, Boehringer Ingelheim, Merck & Co., 3M Health Care, Novartis AG, Omron Healthcare, Inc., PARI Respiratory Equipment, Inc., Sunovion Pharmaceuticals Inc., Philips …
Chronic Obstructive Pulmonary Disease Drugs 2016 Market Segmentation…
The Chronic Obstructive Pulmonary Disease Drugs Market Report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Chronic Obstructive Pulmonary Disease Drugs Industry Report covers the present scenario and the growth prospects of the Chronic Obstructive Pulmonary Disease Drugs Market for 2016-2020.
Health Effect of Forest Bathing Trip on Elderly Patients with Chronic Obstructive Pulmonary Disease.
… it into the document. Forest bathing trip is a short, leisurely visit to forest. In this study we determined the health effects of forest bathing trip on elderly patients with chronic obstructive pulmonary disease (COPD). The patients were randomly …